Magnesium aluminium silicate–gentamicin complex for drug delivery systems
- 238 Downloads
Abstract
This paper presents the characteristics of magnesium aluminium silicate–gentamicin complexes for drug delivery systems. The work describes the results of studies on the successful introduction of gentamicin (an aminoglycoside antibiotic) into the interlayers of smectite clay and examines the possible use of intercalated smectite as a carrier for sustained drug release. Characterisation of magnesium aluminium silicate–gentamicin complexes was carried out by means of X-ray diffraction, Fourier transform infrared spectroscopy, thermal analysis and scanning electron microscopy with EDX analysis. The possibility of using the gentamicin intercalated smectite as a carrier for sustained release of the drug was investigated during in vitro study, in which the release rate of gentamicin from the smectite clay matrix was monitored based on absorption at 330 nm using a UV–Vis spectrometer and the kinetic of drug release was evaluated based on the zero-order, first-order, Higuchi and Korsmeyer–Peppas models. The results confirmed the efficiency of intercalation and indicate the potential for introducing gentamicin into the interlayer space of montmorillonite. Accordingly, the obtained material may thus be used as a drug carrier in modulated drug delivery systems.
Keywords
Clays Gentamicin Drug release Intercalation Biomedical applicationsNotes
Acknowledgements
This study was performed within the framework of funding for statutory activities of AGH University of Science and Technology in Cracow, Faculty of Materials Science and Ceramics (11.11.160.617).
References
- 1.Aguzzi C, Cerezo P, Viseras C, Caramella C. Use of clays as drug delivery systems: possibilities and limitations. Appl Clay Sci. 2007;36:22–36.CrossRefGoogle Scholar
- 2.Chakraborti M, Jackson JK, Plackett D, Gilchrist SE, Burt HM. The application of layered double hydroxide clay (LDH)-poly(lactide-co-glycolic acid) (PLGA) film composites for the controlled release of antibiotics. J Mater Sci Mater Med. 2012;23:1705–13.CrossRefGoogle Scholar
- 3.Mostafavi A, Emami J, Varshosaz J, Davies NM, Rezazadeh M. Development of a prolonged-release gastroretentive tablet formulation of ciprofloxacin hydrochloride: pharmacokinetic characterization in healthy human volunteers. Int J Pharmacol. 2011;409:128–36.CrossRefGoogle Scholar
- 4.de Sousa Rodrigues LA, Figueiras A, Veiga F, Mendes de Freitas R, Nunes LCC, da Silva Cavalcanti, Filho E, da Silva Leite CM. The systems containing clays and clay minerals from modified drug release: a review. Colloids Surf B Biointerfaces. 2013;103:642–51.CrossRefGoogle Scholar
- 5.Takahashi T, Yamada Y, Kataoka K, Nagasaki Y. Preparation of novel PEG-clay hybrid as a DDS material: dispersion stability and sustained release profiles. J Control Release. 2005;107:408–16.CrossRefGoogle Scholar
- 6.Zheng JP, Luan HY, Xi LF, Yao KD. Study on ibuprofen/montmorillonite intercalation composites as drug release system. Appl Clay Sci. 2007;36:297–301.CrossRefGoogle Scholar
- 7.Joshi GV, Patel HA, Kevadiya BD, Bajaj HC. Montmorillonite intercalated with vitamin B1 as drug carrier. Appl Clay Sci. 2009;45:248–53.CrossRefGoogle Scholar
- 8.Pongjanyakul T, Khunawattanakul W, Puttipipatkhachorn S. Physicochemical characterizations and release studies of nicotine–magnesium aluminum silicate complex. Appl Clay Sci. 2009;44:242–50.CrossRefGoogle Scholar
- 9.Kevadiya BD, Joshi GV, Mody HM, Bajaj HC. Biopolymer-clay hydrogel composites as drug carrier: host–guest intercalation and in vitro release study of lidocaine hydrochloride. Appl Clay Sci. 2011;52:364–7.CrossRefGoogle Scholar
- 10.López-Galindo A, Viseras C, Cerezo P. Compositional, technical and safety specifications of clays to be used as pharmaceutical and cosmetics products. Appl Clay Sci. 2007;36:51–63.CrossRefGoogle Scholar
- 11.Konta J. Clay and man: clay raw materials in the service of man. Appl Clay Sci. 1995;10:275–335.CrossRefGoogle Scholar
- 12.Gridi-Bennadji F, Lecomte-Nana GL, Bonnet J-P, Rossignol S. Rheological properties of montmorillonitic clay suspensions: effect of firing and interlayer cations. J Eur Ceram Soc. 2012;32:2809–17.CrossRefGoogle Scholar
- 13.Czimerova A, Jankovic L, Bujdak J. Effect of the exchangeable cations on the spectral properties of methylene blue in clay dispersions. J Colloids Interface Sci. 2004;274:126–32.CrossRefGoogle Scholar
- 14.Mishra RK, Ramasamy K, Lim SM, Ismail MF, Majeed ABA. Antimicrobial and in vitro wound healing properties of novel clay based bionanocomposite films. J Mater Sci Mater Med. 2014;25:1925–39.CrossRefGoogle Scholar
- 15.Lin FH, Lee YH, Jian CH, Wong JM, Shieh MJ, Wang CY. A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier. Biomaterials. 2002;23:1981–7.CrossRefGoogle Scholar
- 16.Choy JH, Choi SJ, Oh JM, Park T. Clay minerals and layered double hydroxides for novel biological applications. Appl Clay Sci. 2007;36:122–32.CrossRefGoogle Scholar
- 17.Tamayo A, Kyziol-Komosinska J, Sánchez MJ, Calejas P, Rubio J, Barba MF. Characterization and properties of treated smectites. J Eur Ceram Soc. 2012;32:2831–41.CrossRefGoogle Scholar
- 18.Rapacz-Kmita A, Stodolak-Zych E, Ziabka M, Rozycka A, Dudek M. Instrumental characterization of the smectite clay–gentamicin hybrids. Bull Mater Sci. 2015;38:1069–78.CrossRefGoogle Scholar
- 19.Yu M, Zhou K, Zhang F, Zhang D. Porous HA microspheres as drug delivery: effects of porosity and pore structure on drug loading and in vitro release. Ceram Int. 2014;40:12617–21.CrossRefGoogle Scholar
- 20.United States Pharmacopeial Convention. Content of gentamicin sulfate. Rockville, MD: United States Pharmacopeial Convention; 2011.Google Scholar
- 21.Clinical guideline for gentamicin prescribing and therapeutic drug monitoring. Royal Cornwall Hospitals NHS; 2014.Google Scholar
- 22.Hadjiioannou TP, Christian GD, Koupparis MA, Macheras PE. Quantitative calculations in pharmaceutical practice and research. New York: VCH Publishers Inc.; 1993.Google Scholar
- 23.Libo Y, Reza F. Zero-order release kinetics from a self-correcting floatable asymmetric configuration drug delivery system. J Pharm Sci. 1996;85:129–248.CrossRefGoogle Scholar
- 24.Gibaldi M, Feldman S. Establishment of sink conditions in dissolution rate determinations. Theoretical considerations and application to nondisintegrating dosage forms. J Pharm Sci. 1967;56:1238–42.CrossRefGoogle Scholar
- 25.Wagner JG. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tables and capsules. J Pharm Sci. 1969;58:1253–7.CrossRefGoogle Scholar
- 26.Higuchi WI. Diffusional models useful in biopharmaceutics drug release rate processes. J Pharm Sci. 1967;56:315–24.CrossRefGoogle Scholar
- 27.Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145–9.CrossRefGoogle Scholar
- 28.Kim H, Fassihi R. Application of binary polimer system in drug release rate modulation 2. Influence of formulation variables and hydrodynamic conditions on release kinetics. J Pharm Sci. 1997;86:323–8.CrossRefGoogle Scholar
- 29.Korsmeyer RW, Guray R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25–35.CrossRefGoogle Scholar
- 30.Raussell-Colom JA, Serratosa JM. Reactions of clays with organic substances. In: Newman ACD, editor. Chemistry of clays and clay minerals. Mineralogical society monograph, vol. 6. Essex: Longman Scientific and Technical; 1987. p. 371–422.Google Scholar
- 31.Parolo ME, Savini MC, Vallés JM, Baschini MT, Avena MJ. Tetracycline adsorption on montmorillonite: pH and ionic strength effects. Appl Clay Sci. 2008;40:179–86.CrossRefGoogle Scholar
- 32.Darder M, Colilla M, Ruiz-Hitzky E. Biopolymer-clay nanocomposites based on chitosan intercalated in montmorillonite. Chem Mater. 2003;15:3774–80.CrossRefGoogle Scholar
- 33.Pongjanyakul T, Priprem A, Puttipipatkhachorn S. Investigation of novel alginate-magnesium aluminum silicate microcomposite films for modified-release tablets. J Control Release. 2005;107:343–56.CrossRefGoogle Scholar
- 34.Legaly G, Dekany I. Adsorption on hydrophobized surfaces: clusters and self-organization. Adv Colloids Interface Sci. 2005;114–115:189–204.CrossRefGoogle Scholar
- 35.Bailey SW, editor. Hydrous phyllosilicates (exclusive of micas). Reviews in mineralogy, vol. 19. Washington, DC: Mineralogical Society of America; 1988.Google Scholar
- 36.Lepoittevin B, Devalckenaere M, Pantoustier N, Alexandre M, Kubies D, Calberg C, Jérôme R, Dubois P. Poly(ɛ-caprolactone)/clay nanocomposites prepared by melt intercalation: mechanical, thermal and rheological properties. Polymer. 2002;43:4017–23.CrossRefGoogle Scholar
- 37.Kiersnowski A, Dabrowski P, Budde H, Kressler J, Piglowski J. Synthesis and structure of poly(ɛ-caprolactone)/synthetic montmorillonite nano-intercalates. Eur Polymer J. 2004;40:2591–8.CrossRefGoogle Scholar
- 38.Katti KS, Sikdar D, Katti DR, Ghosh P, Verma D. Molecular interactions in intercalated organically modified clay and clay-polycaprolactam nanocomposites: experiments and modelling. Polymer. 2006;47:403–14.CrossRefGoogle Scholar
- 39.Doadrio AL, Sousa EMB, Doadrio JC, Perez Pariente J, Izquierdo-Barba I, Vallet-Regi M. Mesoporous SBA-15 HPLC evaluation for controlled gentamicin drug delivery. J Control Release. 2004;97:125–32.CrossRefGoogle Scholar
- 40.Baia M, Astilean S, Iliescu T. Raman and SERS investigations of pharmaceuticals. Berlin: Springer; 2008.CrossRefGoogle Scholar
- 41.Leopold N, Cîntă-Pînzaru S, Baia M, Antonescu E, Cozar O, Kiefer W, Popp J. Raman and surface—enhanced Raman study of thiamine at different pH values. Vib Spectrosc. 2005;39:169–76.CrossRefGoogle Scholar
- 42.Patel HA, Bajaj HC, Jasra RV. Synthesis of Pd and Rh metal nanoparticles in the interlayer space of organically modified montmorillonite. J Nanopart Res. 2008;10:625–32.CrossRefGoogle Scholar
- 43.Viscarra Rossel RA, Lark RM. Improved analysis and modelling of soil diffuse reflectance spectra using wavelets. Eur J Soil Sci. 2009;60:453–64.CrossRefGoogle Scholar
- 44.Amarasinghe PM, Katti KS, Katti DR. Molecular hydraulic properties of montmorillonite: a polarized Fourier transform infrared spectroscopic study. Appl Spectrosc. 2008;62:1303–13.CrossRefGoogle Scholar
- 45.Amarasinghe PM, Katti KS, Katti DR. Nature of organic fluid–montmorillonite interactions: an FTIR spectroscopic study. J Colloids Interface Sci. 2009;337:97–105.CrossRefGoogle Scholar
- 46.Joshi GV, Kevadiya BD, Patel HA, Bajaj HC, Jasra RV. Montmorillonite as drug delivery system: intercalation and in vitro release of timolol maleate. Int J Pharm. 2009;374:53–7.CrossRefGoogle Scholar
- 47.Patel HA, Somani RS, Bajaj HC, Jasra RV. Preparation and characterization of phosphonium montmorillonite with enhanced thermal stability. Appl Clay Sci. 2007;35:194–200.CrossRefGoogle Scholar
- 48.Ambre A, Katti KS, Katti DR. In situ mineralized hydroxyapatite on amino acid modified nanoclays as novel bone biomaterial. Mater Sci Eng C. 2011;31:1017–29.CrossRefGoogle Scholar
- 49.Rafferty DW, Koenig JL. FTIR imaging for the characterization of controlled-release drug delivery applications. J Control Release. 2002;83:29–39.CrossRefGoogle Scholar
- 50.Hoch M, Bandara A. Determination of the adsorption process of tributyltin (TBT) and monobutyltin (MBT) onto kaolinite surface using Fourier transform infrared (FTIR) spectroscopy. Colloids Surf A Physicochem Eng Asp. 2005;253:117–24.CrossRefGoogle Scholar
- 51.Madejowá J. FTIR techniques in clay mineral studies. Vib Spectrosc. 2003;31:1–10.CrossRefGoogle Scholar
- 52.Xu W, Johnston CT, Parker P, Agnew SE. Infrared study of water sorption on Na-, Li-, Ca-, and Mg-exchanged (SWy−1 and SAz−1) montmorillonite. Clays Clay Miner. 2000;48:120–31.CrossRefGoogle Scholar
- 53.Hongping H, Ray FL, Jianxi Z. Infrared study of HDTMA + intercalated montmorillonite. Spectrochimica Acta Part A Mol Biomol Spectrosc. 2004;60:2853–9.CrossRefGoogle Scholar
- 54.Madejowá J, Janek M, Komadel P, Herbert H-J, Moog HC. FTIR analyses of water in MX-80 bentonite compacted from high salinary salt solution systems. Appl Clay Sci. 2002;20:255–71.CrossRefGoogle Scholar
- 55.White JL, Hem SL. Pharmaceutical aspect of clay–organic interaction. Ind Eng Chem Prod Res Dev. 1983;22:665–71.CrossRefGoogle Scholar
- 56.Tomic ZP, Kaluderovic L, Nikolic N, Markovic S, Makreski P. Thermal investigation of acetochlor adsorption on inorganic- and organic-modified montmorillonite. J Therm Anal Calorim. 2016;123:2313–9.CrossRefGoogle Scholar
- 57.Patel HA, Somani RS, Bajaj HC, Jasra RV. Synthesis and characterization of organic bentonite using Gujarat and Rajasthan clays. Curr Sci. 2007;92:1004–9.Google Scholar
- 58.Ni R, Huang Y, Yao C. Therogravimetric analysis of organoclays intercalated with the gemini surfactants. J Therm Anal Calorim. 2009;96:943–7.CrossRefGoogle Scholar
- 59.Soares VLP, Nascimento RSV, Menezes VJ, Batista L. TG characterization of organically modified montmorillonite. J Therm Anal Calorim. 2004;75:671–6.CrossRefGoogle Scholar